The outperformance of value stocks over growth stocks that we mentioned in our last piece (European Equities – what will 2022 bring?) has continued and with vigour. The relative performance of growth against value stocks in January as measured by MSCI has now been worse than any time since 1970s, which suggests to us that the trade is overplayed now.
Based on consensus earnings forecasts for both value and growth stocks, the following picture emerges.
MSCI Europe Value EPS profit growth will be some 39% in 2022 but this declines sharply to just 0.2% in 2023. Consequently, while the PEG this year is certainly attractive at 0.3x, it balloons (to some 47x) in 2023 as earnings growth evaporates. An Average PEG over the period therefore of 24x.
Compare this with MSCI Europe Growth where consensus EPS Growth is just over 11% both this year and next producing a PEG of 2x and 1.85x in 2022 and 2023 respectively. An Average PEG of 1.9x.
For the MSCI Europe index as a whole consensus forecasts for EPS growth are for 30% and 3% growth for 2022 and 2023 respectively producing PEGs of 0.5x and 4.3x which translates into an average PEG of 2.4x.
The above are consensus forecasts for the three indices. As you know the index means next to nothing in our stock picking process. We are confident that the average profit growth for the stocks in our portfolio will be significantly higher than all of the above indices: 43% in 2022 (1x PEG) and 20% in 2023 (PEG of 1.77x) which produces an average PEG of 1.4x.
The picture is much the same for MSCI World Value vs MSCI World Growth indices.
On the basis of the above, we know where our money will be invested.
A PDF version of this article can be found here.
A version of this article was published by Wealth DFM Magazine which can be found here.
This article has been issued by Aubrey Capital Management Limited which is authorised and regulated in the UK by the Financial Conduct Authority and is registered as an Investment Adviser with the US Securities & Exchange Commission. You should be aware that the regulatory regime applicable in the UK may well be different in your home jurisdiction. This article has been prepared solely for the intended recipient for information purposes and is not a solicitation, or an offer to buy or sell any security. The information on which the document is based has been obtained from sources that we believe to be reliable, and in good faith, but we have not independently verified such information and no representation or warranty, express or implied, is made as to their accuracy. All expressions of opinion are subject to change without notice. Any comments expressed in this article should not be taken as a recommendation or advice. Please note that the prices of shares and the income from them can fall as well as rise and you may not get back the amount originally invested. This can be as a result of market movements and of variations in the exchange rates between currencies. Past performance is not a guide to future returns and may not be repeated. Aubrey Capital Management Limited accepts no liability or responsibility whatsoever for any consequential loss of any kind arising out of the use of this article or any part of its contents. This article does not in any way constitute investment advice or an offer or invitation to deal in securities. Recipients should always seek the advice of a qualified investment professional before making any investment decisions.